Related Experiment Video
Updated: Jan 1, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
Itaru Tojyo1, Yukari Shintani1, Takashi Nakanishi1
11Department of Oral and Maxillofacial Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama 641-8509 Japan.
Background:
Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule that attenuates the immune response. PD-L1 contributes to failed antitumor immunity; thereby, blockade of PD-L1 with monoclonal antibody enhances the immune response. Recently, it was reported that PD-L1 was regulated by protein 53 (p53). Besides, cytokeratin 17 (CK17) is thought to be a diagnostic marker of oral squamous cell carcinoma (OSCC). Our aim was to evaluate the correlation between the immunohistochemical expression of PD-L1, p53 and CK17 with clinicopathological characteristics and disease-specific survival in patients with OSCC.
Methods:
A total of 48 patients with OSCC were included in this study. Immunohistochemical staining was performed to evaluate the correlation among the expressions of PD-L1, p53 and CK17, and furthermore the correlation among various clinicopathological factors, PD-L1, p53 and CK17.
Results:
The positive rate of p53, CK17, PD-L1 (tumor cells) and PD-L1 (tumor-infiltrating lymphocytes) was 63.2%, 91.7%, 48.9% and 57.1%. A statistically significant correlation between p53 expression and T stage and TNM stage (p = 0.049, p = 0.03, respectively) was observed. Also, a statistically significant correlation between p53 and PD-L1 (TCs) expression (p = 0.0009) was observed. Five-year disease-specific survival rate was not significantly correlated with gender, TNM stage, p53 expression, PD-L1 expression and CK17 expression.
Conclusion:
The expression of p53 and PD-L1 shows significantly positive correlation in oral squamous cell carcinoma in tumor cells. Also, a significant correlation between p53 expression and T stage and TNM stage was observed. No other significant correlation between PD-L1 staining or CK17 and clinical or pathologic characteristics was identified.
Insights
In oral squamous cell carcinoma (OSCC), p53 and programmed cell death ligand 1 (PD-L1) expression in tumor cells are positively correlated. However, neither PD-L1 nor cytokeratin 17 (CK17) expression showed significant links to survival or other clinical factors in OSCC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Programmed cell death ligand 1 (PD-L1) is an immune checkpoint molecule that can hinder antitumor immunity.
- PD-L1 regulation by protein 53 (p53) and its role in oral squamous cell carcinoma (OSCC) are under investigation.
- Cytokeratin 17 (CK17) is a potential diagnostic marker for OSCC.
Purpose of the Study:
- To investigate the correlation between immunohistochemical expression of PD-L1, p53, and CK17.
- To evaluate the relationship of these markers with clinicopathological characteristics in OSCC patients.
- To assess the association of these markers with disease-specific survival in OSCC.
Main Methods:
- Immunohistochemical staining was performed on samples from 48 OSCC patients.
- Expression levels of PD-L1, p53, and CK17 were analyzed.
- Correlations with clinicopathological factors and survival data were statistically evaluated.
Main Results:
- Positive rates were: p53 (63.2%), CK17 (91.7%), PD-L1 on tumor cells (48.9%), and PD-L1 on tumor-infiltrating lymphocytes (57.1%).
- p53 expression significantly correlated with T stage (p=0.049) and TNM stage (p=0.03).
- A significant positive correlation was found between p53 and PD-L1 expression in tumor cells (p=0.0009).
Conclusions:
- p53 and PD-L1 expression in tumor cells are significantly correlated in OSCC.
- p53 expression is associated with advanced T and TNM stages in OSCC.
- No significant correlation was found between PD-L1 or CK17 and other clinical/pathological characteristics or survival.
